Karbicombi (Hydrochlorothiazide, Candesartan Cilexetil)

Karbicombi is used to treat hypertension, a common cardiovascular disorder characterized by chronically elevated arterial pressure that increases the risk of heart attack, stroke, and kidney disease.

• Hypertension: lowers both systolic and diastolic blood pressure, facilitating achievement of guideline‑recommended targets and reducing strain on the heart.
• Essential hypertension: combines vasodilatory action of candesartan with diuretic effect of hydrochlorothiazide to control persistent elevated pressure when monotherapy is insufficient.
• High blood pressure: improves overall cardiovascular risk profile by decreasing fluid volume and peripheral resistance, supporting long‑term organ protection.

• Candesartan blocks angiotensin II type 1 (AT₁) receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing extracellular fluid volume. The combined actions result in decreased peripheral vascular resistance and lowered blood volume, producing an additive antihypertensive effect. This dual mechanism provides more consistent blood pressure control across a range of patients and helps mitigate compensatory mechanisms that can limit the efficacy of single‑agent therapy.

Karbicombi may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness or light‑headedness: may occur especially after the first dose.
• Increased urination: due to the diuretic component.
• Electrolyte disturbances (e.g., low potassium or sodium): mild imbalances may be detected.
• Headache: transient headache reported by some patients.

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance: can lead to muscle cramps or arrhythmia.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Acute kidney injury: sudden loss of renal function, particularly in volume‑depleted patients.
• Significant drop in blood pressure (hypotension): may cause fainting.

When prescribing Karbicombi, clinicians should consider several precautionary measures to ensure safe use.

• Monitor electrolytes: check serum potassium and sodium regularly, especially during initiation.
• Assess renal function: evaluate creatinine and eGFR before and during therapy.
• Use caution in elderly: increased sensitivity to blood pressure lowering and dehydration.
• Avoid in severe hepatic impairment: drug metabolism may be altered.
• Review concomitant medications: NSAIDs, lithium, and other antihypertensives may affect efficacy or safety.
• Store at room temperature: keep tablets in the original container, protect from moisture and light.

Karbicombi can interact with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined renin‑angiotensin blockade may increase risk of renal impairment, hyperkalemia, and hypotension.
• Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause dangerous hyperkalemia.
• Lithium: thiazide component reduces lithium clearance, raising risk of lithium toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• ACE inhibitors: additive effect on potassium and renal function; monitor labs.
• Beta‑blockers: may enhance blood pressure lowering; watch for symptomatic hypotension.